A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas.
Kim SJ, Shin DY, Kim JS, Yoon DH, Lee WS, Lee H, Do YR, Kang HJ, Eom HS, Ko YH, Lee SH, Yoo HY, Hong M, Suh C, Kim WS.
Kim SJ, et al. Among authors: lee sh, lee h, lee ws.
Ann Oncol. 2016 Apr;27(4):712-8. doi: 10.1093/annonc/mdv624. Epub 2016 Feb 8.
Ann Oncol. 2016.
PMID: 26861608
Free article.
Clinical Trial.